Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia

Cancer Gene Therapy

Volumn 23, Issue 10, 2016, Pages 327-332

  Fathullahzadeh, S ^a   Mirzaei, H ^b   Honardoost, M A ^c   Sahebkar, A ^b   Salehi, M ^d  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF ISFAHAN   (Iran)

^d ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; MICRORNA 192; PROTEIN BCL 2; PROTEIN P53; SMALL NUCLEAR RNA; CDKN1A PROTEIN, HUMAN; MICRORNA; MIRN192 MICRORNA, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CELL CYCLE ARREST; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; VERY ELDERLY; WESTERN BLOTTING; BLOOD; CASE CONTROL STUDY; CELL CYCLE; DISEASE EXACERBATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; MONONUCLEAR CELL;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MALE; MICRORNAS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84988649829     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2016.34     Document Type: Article

References (31)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
2. Li S, Moffett HF, Lu J, Werner L, Zhang H, Ritz J et al. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PloS One 2011; 6: e16956.
3. Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. Relationship between p53 dysfunction, CD38 expression, and IgV H mutation in chronic lymphocytic leukemia. Blood 2002; 100: 1404-1409.
4. Fernando TR, Rodriguez-Malave NI, Rao DS. MicroRNAs in B cell development and malignancy. J Hematol Oncol 2012; 5: 7.
5. Moussay E, Wang K, Cho J-H, van Moer K, Pierson S, Paggetti J et al. MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2011; 108: 6573-6578.
6. Calin GA, Liu C-G, Sevignani C, Ferracin M, Felli N, Dumitru CD et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101: 11755-11760.
7. Teimori H, Ashoori S, Akbari MT, Naeini MM, Chaleshtori MH. FISH Analysis for del6q21 and del17p13 in B-cell chronic lymphocytic leukemia in Iranians. Iran Red Crescent Med J 2013; 15: 107.
8. Zent CS. Time to test CLL p53 function. Blood 2010; 115: 4154-4155.
9. Gholamin S, Pasdar A, Sadegh Khorrami M, Mirzaei H, Reza Mirzaei H, Salehi R et al. The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment. Curr Pharm Des 2016; 22: 397-403.
10. Mirzaei H, Gholamin S, Shahidsales S, Sahebkar A, Jafaari MR, Mirzaei HR et al. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. Eur J Cancer 2016; 53: 25-32.
11. Simonian M, Mosallayi M, Mirzaei H. Circulating miR-21 as novel biomarker in gastric cancer: diagnostic and prognostic biomarker. Cancer Res Ther 2016.
12. Reza Mirzaei H. Circulating microRNAs in hepatocellular carcinoma: potential diagnostic and prognostic biomarkers. Curr Pharm Des 2016 (e-pub ahead of print).
13. Salarini R, Sahebkar A, Mirzaei H, Jaafari M, Riahi M, Hadjati J et al. Epi-drugs and Epi-miRs: moving beyond current cancer therapies. Curr Cancer Drug Targets 2015 (e-pub ahead of print).
14. Bueno MJ, Malumbres M. MicroRNAs and the cell cycle. Biochim Biophys Acta 2011; 1812: 592-601.
15. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008; 68: 10094-10104.
16. Pettitt A, Sherrington P, Cawley J. The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 1049-1051.
17. Geng L, Chaudhuri A, Talmon G, Wisecarver JL, Are C, Brattain M et al. MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene 2014; 33: 5332-5340.
18. Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang Q et al. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncol Rep 2014; 31: 1863-1870.
19. Di Lisio L, Sánchez-Beato M, Gómez-López G, Rodríguez ME, Montes-Moreno S, Mollejo M et al. MicroRNA signatures in B-cell lymphomas. Blood Cancer J 2012; 2: e57.
20. Georges SA, Biery MC, Kim S-y, Schelter JM, Guo J, Chang AN et al. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res 2008; 68: 10105-10112.
21. Negrini M, Cutrona G, Bassi C, Fabris S, Zagatti B, Colombo M et al. microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters. Clin Cancer Res 2014; 20: 4141-4153.
22. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 2009; 37: D105-D110.
23. Hsu S-D, Lin F-M, Wu W-Y, Liang C, Huang W-C, Chan W-L et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res 2011; 39: D163-169.
24. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
25. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30.
26. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
27. Decker T, Schneller F, Miething C, Jahn T, Duyster J, Peschel C. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia. 08876924. 2002; 16: 327-334.
28. Leupin N, Cenni B, Novak U, Hügli B, Graber HU, Tobler A et al. Disparate expression of the PTEN gene: a novel finding in B-cell chronic lymphocytic leukaemia (B-CLL). Br J Haematol 2003; 121: 97-100.
29. Majid A, Tsoulakis O, Walewska R, Gesk S, Siebert R, Kennedy DBJ et al. BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 - 938 A4 C promoter single nucleotide polymorphism. Blood 2008; 111: 874-877.
30. McKeller MR, Robetorye RS, Dahia PL, Aguiar RC. Integrity of the CBL gene in mature B-cell malignancies. Blood 2009; 114: 4321-4322.
31. Bernard P, Fleming A, Lacombe A, Harley VR, Vilain E. Wnt4 inhibits β-catenin/TCF signalling by redirecting β-catenin to the cell membrane. Biol Cell 2008; 100: 167-177.